Addex Therapeutics Ltd (SWX:ADXN)

-8.73% (1Y)

Market Cap	5.96M
Revenue (ttm)	410.04K
Net Income (ttm)	7.06M
Shares Out	98.34M
EPS (ttm)	0.07
PE Ratio	0.84
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,666,130
Average Volume	215,595
Open	0.0600
Previous Close	0.0570
Day's Range	0.0598 - 0.0630
52-Week Range	0.0472 - 0.1095
Beta	1.99
RSI	56.90
Earnings Date	May 19, 2025

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ADXN